NICE

News

NICE turns down NHS use of Roche's breast cancer drug Itovebi, which the company says reveals a flaw in the appraisal of combination therapies.

Market Access

Operational review meeting minutes released by the DHSC reveal industry and government are planning to move to a 7-year agreement.

News

Patients in England and Wales with familial chylomicronaemia syndrome will soon have a new treatment option, as NICE backs Sobi's Tryngolza.

Market Access

Leela Barham looks at the discussion on non-submissions to the HTA body NICE, informed by the latest metrics for VPAG.

News

The chairs of six UK parliamentary committees have asked the National Audit Office to investigate the UK-US pharma deal and its impact on the NHS.

News

Almost three years after Enhertu was made available in Scotland, the drug is finally an option for patients in England with HER2-low breast cancer.